×
About 113 results

ALLMedicine™ Factor IX Deficiency Center

Research & Reviews  30 results

Hemophilia B (Factor IX Deficiency).
https://doi.org/10.1016/j.hoc.2021.07.008
Hematology/oncology Clinics of North America; Sidonio RF, Malec L

Oct 6th, 2021 - The biology of factor IX deficiency leading to hemophilia B has important distinctions from factor VIII deficiency that leads to hemophilia A. In this article, the authors explore the unique biology of factor IX in hemostasis, including the import...

Human coagulation factor IX: a systematic review of its characteristics.
https://doi.org/10.1097/MBC.0000000000001076
Blood Coagulation & Fibrinolysis : an International Journ... Yin R, Liu C

Aug 20th, 2021 - Human coagulation factor IX (FIX) is a vitamin K dependent glycoprotein. It is used in therapy of factor IX deficiency, known as haemophilia B. This article explained the coagulation process involved in FIX and the principle of haemophilia B cause...

Health care resource utilization and cost burden of hemophilia B in the United States.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045501
Blood Advances; Buckner TW, Bocharova I et. al.

Apr 9th, 2021 - Hemophilia B is a rare congenital blood disorder characterized by factor IX deficiency. Clinical profiles of hemophilia B range from mild to severe forms of the disease. The objective of this study was to characterize the economic burden associate...

The changing treatment landscape in haemophilia: from standard half-life clotting facto...
https://doi.org/10.1016/S0140-6736(20)32722-7
Lancet (London, England); Mancuso ME, Mahlangu JN et. al.

Jan 19th, 2021 - Congenital haemophilia A (factor VIII deficiency) and B (factor IX deficiency) are X-linked bleeding disorders. Replacement therapy has been the cornerstone of the management of haemophilia, aiming to reduce the mortality and morbidity of chronic ...

The Effects of Exercise Training in Children With Hemophilia
https://clinicaltrials.gov/ct2/show/NCT04703062

Jan 12th, 2021 - Hemophilia is defined as bleeding in the musculoskeletal system and soft tissues as a result of the lack of clotting factors in the blood. Recurrent attacks of hemarthrosis cause pain, also because of the pain patients tend to use joints less than...

see more →

Drugs  7 results see all →

Clinicaltrials.gov  1 results

The Effects of Exercise Training in Children With Hemophilia
https://clinicaltrials.gov/ct2/show/NCT04703062

Jan 12th, 2021 - Hemophilia is defined as bleeding in the musculoskeletal system and soft tissues as a result of the lack of clotting factors in the blood. Recurrent attacks of hemarthrosis cause pain, also because of the pain patients tend to use joints less than...

see more →

News  7 results

Study finds higher than expected rates of hemophilia in Indiana
https://www.mdedge.com/hematology-oncology/article/198614/bleeding-disorders/study-finds-higher-expected-rates-hemophilia?channel=39313
Caleb Rans

Apr 10th, 2019 - The state of Indiana had higher hemophilia incidence and prevalence rates, compared with national estimates, according to results from a statewide epidemiologic analysis. “[The study] aimed to identify all persons with hemophilia, including those.

CHMP Backs Orphan Drug Refixia for Hemophilia B
https://www.medscape.com/viewarticle/877724

Mar 24th, 2017 - The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommend nonacog beta pegol (Refixia, Novo Nordisk A/S) for the treatment and prophylaxis of bleeding in patients aged 12 years and older with hemophili...

Hemophilia B: Lentiviral Vector Safe, Effective in Dogs
https://www.medscape.com/viewarticle/840943

Mar 5th, 2015 - Lentiviral vectors effectively deliver the gene that encodes coagulation factor IX (FIX) to the liver in dogs with naturally occurring hemophilia B (factor IX deficiency), researchers report in an article published in the March 4 issue of Science ...

Rixubis Recommended by EMA Panel for Hemophilia B
https://www.medscape.com/viewarticle/833935

Oct 27th, 2014 - The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for nonacog gamma (Rixubis, Baxter Innovations GmbH) for prophylaxis and treatment of bleeding in patients...

Rixubis Recommended by EMA Panel for Hemophilia B
https://www.staging.medscape.com/viewarticle/833935

Oct 27th, 2014 - The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for nonacog gamma (Rixubis, Baxter Innovations GmbH) for prophylaxis and treatment of bleeding in patients...

see more →